The PRO-ACT database: design, initial analyses, and predictive features - Wikidata - wikimedia - TriplyDB

The PRO-ACT database: design, initial analyses, and predictive features

The PRO-ACT database: design, initial analyses, and predictive features

http://www.wikidata.org/entity/Q28651661

about

Crowdsourcing biomedical research: leveraging communities as innovation engines Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?Amyotrophic Lateral Sclerosis Survival Score (ALS-SS): A simple scoring system for early prediction of patient survival.How common are ALS plateaus and reversals?Predicting disease progression in amyotrophic lateral sclerosis.Open Access Platforms in Spinal Cord Injury: Existing Clinical Trial Data to Predict and Improve Outcomes.Predicting functional decline and survival in amyotrophic lateral sclerosis.Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.ALS biomarkers for therapy development: State of the field and future directions.Structural and diffusion imaging versus clinical assessment to monitor amyotrophic lateral sclerosis.The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials Urinary p75ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS.The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders.Urate Levels Predict Survival in ALS: Analysis of the Expanded PRO-ACT Database.Patients with ALS show highly correlated progression rates in left and right limb muscles.Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis.Urate as a Marker of Risk and Progression of Neurodegenerative Disease.Serum urate at trial entry and ALS progression in EMPOWER.Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.Individual treatment effect prediction for amyotrophic lateral sclerosis patients.Complete hazard ranking to analyze right-censored data: An ALS survival study.Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS.Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort.Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials.Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis.A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials.An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe.Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations.Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression.Disease progression in C9orf72 mutation carriers.Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis.Quantifying disease progression in amyotrophic lateral sclerosis using peripheral nerve sonography.Modeling the course of amyotrophic lateral sclerosis.Improved stratification of ALS clinical trials using predicted survival.Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS.Unraveling the Complexity of Amyotrophic Lateral Sclerosis Survival Prediction.ALSUntangled No. 37: Inosine*ALSUntangled No. 34: GM604

P2860

Q27887654-E964323C-B9DE-46FA-A522-A333388361C1 Q28601965-7065B93B-7184-4F35-A7AE-8957A31C451B Q28649394-E135E339-7F3D-4979-8719-CC60155A3E34 Q30488423-BF155869-066D-469A-A409-9CA97369EC88 Q30488673-B9C176B7-1F60-4FA5-8394-0A8545CE3432 Q30490321-5BD8346A-8ADB-4C55-9696-2EB66EC440FA Q30490749-E28305B3-A6CE-4B76-B50B-15F49912167D Q33562655-49A689FF-2A73-4043-8C25-37F4CC56D5F0 Q35854192-260BE62F-9BCE-49A8-A2AC-9334ED3F73F1 Q36479616-41106E1F-5A18-47D3-A7FD-2E3903D0C02F Q36787328-032D565C-2695-46AE-965E-95520092A859 Q37107393-957CD4B4-5D74-49D6-A6B3-FAA9D6C633BA Q37158966-7C2D75E1-9012-42BA-A08C-49B10CFBF494 Q37730505-4BDC642A-9632-438E-8F7A-47EA75D16B7B Q38522643-8A39A907-98F3-46E7-B7AE-6A0C0962691C Q38600633-E37F850B-80F8-4625-A4B6-A27D46035104 Q38733015-4E439877-C55D-4B25-9D3E-FEAA818C531A Q38760817-C9E33C00-6439-4957-9F85-8AB37C0BC35B Q39044143-A896161F-AF97-40BC-B7DF-F6CFFD8C7CD8 Q40563709-9324B019-0C0B-4F9D-912F-5614657764DB Q46084639-4D86E424-40AB-4A23-9815-97D2051A7F10 Q47213485-DC0D8186-54EB-4F15-A275-41EC00B9C689 Q47238514-DA4A64EA-B11E-40C6-A175-925A1CC34963 Q47648367-0B888240-BCAA-4F06-9353-DE912F18FD74 Q47680014-1B432331-FE0E-4393-BEA3-976F3E64DF03 Q47688852-5E746BC5-6BA8-4B07-8EFF-3B7BA3C34826 Q47764404-4EA423DC-203D-4EEA-B358-0F5E13D43F4F Q47772089-CF4ADEEC-6E92-4DD3-93FA-E9AD54112CCD Q47782678-8B5A4E3E-78F6-4318-B2D3-C51898699B37 Q48033726-2F4B8AD9-A728-4CC8-BD97-EED7966020D4 Q49222007-49854E8D-3DB7-4543-931A-99618C1B818B Q50584457-F7BF0FDF-18DC-456D-BC82-89452D38EA0B Q51733178-C4BE08A6-AAE5-44A2-96D3-4D3961C8D104 Q53185951-32559F25-1311-49D3-B636-58705B71297C Q53648700-DC3D0C30-A459-4A98-8701-F254CD1BF538 Q55054303-5D796C0D-A8BA-4283-94BC-1B7148460188 Q55245121-41EEAD6F-87F9-447B-AE5A-12D1BA9A9DEC Q55368834-FB285085-7D3E-4C74-8729-2CB354C9C55A Q57464278-2487BE00-0242-4423-BC18-E6B12A65E7D2 Q57464289-A2E2CE78-77A9-4E99-84E2-FD8B6AE320A1

P2860

The PRO-ACT database: design, initial analyses, and predictive features

http://www.wikidata.org/entity/Q28651661

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The PRO-ACT database: design, initial analyses, and predictive features

@ast

The PRO-ACT database: design, initial analyses, and predictive features

@en

The PRO-ACT database: design, initial analyses, and predictive features

@nl

type

label

The PRO-ACT database: design, initial analyses, and predictive features

@ast

The PRO-ACT database: design, initial analyses, and predictive features

@en

The PRO-ACT database: design, initial analyses, and predictive features

@nl

prefLabel

The PRO-ACT database: design, initial analyses, and predictive features

@ast

The PRO-ACT database: design, initial analyses, and predictive features

@en

The PRO-ACT database: design, initial analyses, and predictive features

@nl

P1433

Q28651661-C3FB646B-725F-41B9-9F7E-A831C05EA317

P1476

Q28651661-D30664B3-A8D9-408D-9B66-A2B5C2730D50

P2093

Q28651661-17E83EBF-EFC4-4C2B-BE26-AD9F41C5E81D

Q28651661-2FFEDCAF-9CEA-4184-AD7C-1477D1AF94A3

Q28651661-63B28F4F-ABA6-4AD9-A4ED-6BCB809DCA13

Q28651661-6B1CF4D8-C921-4B38-8B12-7CAF1E19EFE7

Q28651661-7C4E84BE-FF0D-46A9-AAD7-BFAB131D814A

Q28651661-80A850D8-8219-4418-800B-7247CCCE6031

Q28651661-84DC057A-9BDC-49F6-9CDF-ADD301FA56EF

Q28651661-D55688CC-FC1B-4A13-85E1-31A3E3EE6D69

Q28651661-DBFB2C4D-F1C5-421B-9D44-B85936E93547

Q28651661-EE5F56D3-D548-4976-9D30-27EB7664F6C5

P2860

Q28651661-037FCDBE-BD95-4186-AB10-7DB4B06419D5

Q28651661-07C79DF7-8852-4692-9FC5-9541BDD50D00

Q28651661-0902259A-00AB-49EC-A96C-0B9EAAD6A1B4

Q28651661-431BA545-CE12-4992-825A-02061DFFC966

Q28651661-465B024F-530F-4842-B97F-EB0B4EA0E52B

Q28651661-47DFC108-F429-4383-8229-B66517983304

Q28651661-54D47C8E-C76F-447A-BB31-96BECDC2E35D

Q28651661-5E7F17E7-AB11-4722-B808-5D10315D80EB

Q28651661-61237E4F-28DB-4F64-92C9-E85E08D00FE8

Q28651661-762DE084-D954-42EC-816B-69E91286A31C

P304

Q28651661-40113C8E-BEB1-445E-A284-A4CBC06C490C

P31

Q28651661-7F6427D9-E860-48BA-8289-C18DE0351908

P3181

Q28651661-46BA075C-C6AD-4BE5-AAFB-09D785E5319B

P356

Q28651661-32E60C4A-D044-48C0-B210-536C962BCFDD

P407

Q28651661-7A1A29D2-95FD-4FA8-84C3-693808767E08

P433

Q28651661-6D5CC38D-EB8C-474F-B0F0-340D4084C9C1

P478

Q28651661-FD15E6CB-A5C8-4F52-9E8F-59A58BC0C9D1

P50

Q28651661-EDFBBDE0-5CBF-4E20-92DD-3D33424E572C

P577

Q28651661-E4A7B8B7-5431-469F-9055-8940F442EF0F

P698

Q28651661-57A84FA6-7046-4CE6-AB6C-02B47560BFD0

P921

Q28651661-A1FF0850-93EF-4DF7-AA4D-1297B810CD6E

P932

Q28651661-012911BA-5AD4-482D-9DAF-7D2E754F23F0

P3181

P356

WNL.0000000000000951

P1433

P1476

The PRO-ACT database: design, initial analyses, and predictive features

@en

P2093

Alexander Sherman

http://www.w3.org/2001/XMLSchema#string

Amy Shui

http://www.w3.org/2001/XMLSchema#string

David Schoenfeld

http://www.w3.org/2001/XMLSchema#string

Ervin Sinani

http://www.w3.org/2001/XMLSchema#string

Igor Katsovskiy

http://www.w3.org/2001/XMLSchema#string

James Berry

http://www.w3.org/2001/XMLSchema#string

Jason Walker

http://www.w3.org/2001/XMLSchema#string

Melanie Leitner

http://www.w3.org/2001/XMLSchema#string

Nazem Atassi

http://www.w3.org/2001/XMLSchema#string

Neta Zach

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II/III randomized trial of TCH346 in patients with ALS

Amyotrophic lateral sclerosis

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.

Amyotrophic lateral sclerosis disease progression model.

The relationship between uric acid levels and Huntington's disease progression

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force.

Urate as a predictor of the rate of clinical decline in Parkinson disease.

Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials.

P304

1719-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3628137

http://www.w3.org/2001/XMLSchema#string

P356

10.1212/WNL.0000000000000951

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P50

Merit E Cudkowicz

P577

2014-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25298304

http://www.w3.org/2001/XMLSchema#string

P921

P932

4239834

http://www.w3.org/2001/XMLSchema#string